PRLD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Prelude Therapeutics Inc (PRLD) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the technical indicators show some bullish momentum and the company has demonstrated significant revenue growth, the lack of positive news, weak financial performance in terms of net income and EPS, and no significant trading trends from hedge funds or insiders make it a less compelling investment right now. Additionally, the absence of Intellectia Proprietary Trading Signals further supports a cautious approach.
The technical indicators show a bullish trend with moving averages (SMA_5 > SMA_20 > SMA_200) and a positive MACD histogram of 0.1. RSI is neutral at 61.116, indicating no overbought or oversold conditions. The stock is trading above the pivot level (2.629) with resistance levels at 3.129 and 3.439, suggesting some upside potential. However, the pre-market price of 2.93 is close to the first resistance level, limiting immediate gains.
Revenue growth of 116.67% YoY in Q3 2025, indicating strong top-line performance. Gross margin remains at 100%, showcasing operational efficiency.
Net income dropped by -38.88% YoY, and EPS declined by -39.53% YoY, reflecting poor profitability. No significant trading trends from hedge funds or insiders. No recent news or event-driven catalysts. No Intellectia Proprietary Trading Signals present.
In Q3 2025, revenue increased to $6.5M, up 116.67% YoY, but net income dropped to -$19.73M, down -38.88% YoY. EPS also declined to -0.26, down -39.53% YoY. Gross margin remained stable at 100%.
No data available for analyst ratings or price target changes.
